ѻý

Higher Rybelsus Doses More Effective; Insulin Cap for All? Win for GLP-1/GIP Drug

<ѻý class="mpt-content-deck">— News and commentary from the endocrinology world
MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

In the phase III PIONEER PLUS trial, 50- and 25-mg doses of were significantly better at reducing HbA1c levels and weight in patients with type 2 diabetes compared with a 14-mg dose when added to stable doses of other oral antidiabetics, Novo Nordisk announced.

An estimated 80% of paper receipts from major store chains in the U.S. use "toxic chemicals," such as bisphenol A (BPA), according to a .

Certain may help predict development of type 1 diabetes later in life. (Diabetologia)

There's a renewed bipartisan push in the Senate to with private insurance -- not just for those with Medicare. (The Hill)

Viking Therapeutics' investigational yielded a 6% greater average weight loss in patients with obesity compared with placebo within 28 days in a phase I trial. A phase II dose-escalation trial is planned for later this year, the developer said.

The -- once thought of as a "safer" alternative to phthalates -- was found to disrupt brain health in a cell culture study presented at the American Society for Biochemistry and Molecular Biology annual meeting.

A for a 12-year-old boy has left one family paying an $872 monthly bill. (USA Today)

Yale School of Medicine announced the establishment of its new to be led by Ania Jastreboff, MD, PhD.

Transgender patients say that can be more traumatizing than they're worth, and they often have little access to affordable healthcare. (Washington Post)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.